GPhA And Actavis Divorcing: Biosimilars Behind The Rift
Actavis, the hybridizing generics giant that once helped keep GPhA together, now appears to be splitting off in a dispute over state substitution strategy.
You may also be interested in...
New CEO Chip Davis wants GPhA sitting at the table in policy debates rather than being on the menu, but industry consolidation means there are fewer dues-paying members to fill the chairs.
Chip Davis still believes in innovation, but now must balance that with affordability in new role leading the generic association.
Brand companies welcome but unlikely to join because of policy differences; educational handbook compares biosimilars to biologic manufacturing changes.